Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPersonalized MedicinePivotal Practice Views with the Oncology BrothersPodcastsSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Myeloma
  • Chronic Lymphocytic Leukemia
  • Gynecologic Cancers
  • Genomic Testing
  • Melanoma
  • Genitourinary Cancers
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Emerging Trends in Head and Neck Cancer Treatment: Advanced Imaging Modalities and Personalized Therapy

August 10, 2024
By Christina Henson, MD
Opinion
Video

Christina Henson, MD, discusses unmet needs among patients with head and neck cancer.

Christina Henson, MD, radiation oncologist at The University of Oklahoma, discusses unmet needs among patients with head and neck cancer. Here, she discusses studies investigating how to best customize treatment for these patients, especially regarding deescalating treatment to avoid unnecessary toxicities.

Transcription:

0:05 | So far, we haven't found the kind of magic solution or the best way to deescalate on a large scale, but there have been a lot of really promising smaller studies selecting more niche groups of patients either with advanced imaging modalities that aren't necessarily available everywhere but that are able to kind of measure the tumor biology during the course of treatment and use that to determine who's having a good response and who's not having a good response and have the option to stop treatment earlier at lower doses for patients who are responding well.

0:45 | So everyone's hopeful that some time in the near future one of or more than one of is these studies will pan out in a widely applicable way that will be very beneficial for our patients.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content

NEO-MEL-T Study: Mooradian Explores TIM-3/PD-1 in Resectable Melanoma

NEO-MEL-T Study: Mooradian Explores TIM-3/PD-1 in Resectable Melanoma

Sabrina Serani
June 24th 2025
Article

Read More


Hochhaus on ASC4START and Asciminib’s Superior Tolerability in CML-CP

Hochhaus on ASC4START and Asciminib’s Superior Tolerability in CML-CP

Jordyn Sava
June 23rd 2025
Article

Read More


Adjuvant Pembrolizumab in Kidney Cancer: Dr Haas on KEYNOTE-564

Adjuvant Pembrolizumab in Kidney Cancer: Dr Haas on KEYNOTE-564

Sabrina Serani
June 19th 2025
Article

Read More


Dr Loong on Sevabertinib in HER2-Mutant NSCLC: SOHO-01 Trial Insights

Dr Loong on Sevabertinib in HER2-Mutant NSCLC: SOHO-01 Trial Insights

Jordyn Sava
June 19th 2025
Article

Sevabertinib shows promise as a targeted therapy for HER2-mutant non-small cell lung cancer, addressing significant treatment gaps in this area.

Read More


Unveiling the Unseen: The Future of Posttreatment Cancer Detection

Unveiling the Unseen: The Future of Posttreatment Cancer Detection

Sabrina Serani
June 17th 2025
Article

Advancements in cancer care focus on precise detection of measurable residual disease, enhancing monitoring and relapse prediction through innovative technologies and AI integration.

Read More


Deepening Our Understanding of CAR T Manufacturing: A Novel Profiling Platform

Deepening Our Understanding of CAR T Manufacturing: A Novel Profiling Platform

Sabrina Serani
June 16th 2025
Article

A new platform comprehensively profiles CAR T-cells during manufacturing, revealing phenotypic shifts. This allows for shorter timelines, better outcomes, and personalized therapies.

Read More

Related Content

NEO-MEL-T Study: Mooradian Explores TIM-3/PD-1 in Resectable Melanoma

NEO-MEL-T Study: Mooradian Explores TIM-3/PD-1 in Resectable Melanoma

Sabrina Serani
June 24th 2025
Article

Read More


Hochhaus on ASC4START and Asciminib’s Superior Tolerability in CML-CP

Hochhaus on ASC4START and Asciminib’s Superior Tolerability in CML-CP

Jordyn Sava
June 23rd 2025
Article

Read More


Adjuvant Pembrolizumab in Kidney Cancer: Dr Haas on KEYNOTE-564

Adjuvant Pembrolizumab in Kidney Cancer: Dr Haas on KEYNOTE-564

Sabrina Serani
June 19th 2025
Article

Read More


Dr Loong on Sevabertinib in HER2-Mutant NSCLC: SOHO-01 Trial Insights

Dr Loong on Sevabertinib in HER2-Mutant NSCLC: SOHO-01 Trial Insights

Jordyn Sava
June 19th 2025
Article

Sevabertinib shows promise as a targeted therapy for HER2-mutant non-small cell lung cancer, addressing significant treatment gaps in this area.

Read More


Unveiling the Unseen: The Future of Posttreatment Cancer Detection

Unveiling the Unseen: The Future of Posttreatment Cancer Detection

Sabrina Serani
June 17th 2025
Article

Advancements in cancer care focus on precise detection of measurable residual disease, enhancing monitoring and relapse prediction through innovative technologies and AI integration.

Read More


Deepening Our Understanding of CAR T Manufacturing: A Novel Profiling Platform

Deepening Our Understanding of CAR T Manufacturing: A Novel Profiling Platform

Sabrina Serani
June 16th 2025
Article

A new platform comprehensively profiles CAR T-cells during manufacturing, revealing phenotypic shifts. This allows for shorter timelines, better outcomes, and personalized therapies.

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Editorial Board
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.